quote:"I had a great time educating the kids about gene therapy and CF in a playful way, and there were some very interesting conversations with the parents.",
summary:[<p><OurLinktabId='teutoruft'scrollToId="teuroruft-heading"path=''text="Der Teuto ruft!"/> is a community event in Bielefeld where iGEM Bielefeld participated to raise awareness about Cystic Fibrosis (CF) and gene therapy. They engaged children through interactive experiments, such as creating lung models and simulating mucus to help them understand the challenges faced by CF patients. Adults were informed about their gene therapy project and had meaningful discussions about the implications of CF treatment. Collaborating with other institutions like the life science student initiative btS, the team expanded their outreach. Despite changeable weather, the event was a success in educating the public and improving science communication.</p>],
summary:[<p><OurLinktabId='teutoruft'scrollToId="teuroruft-heading"path='human-practices'text="Der Teuto ruft!"/> is a community event in Bielefeld where iGEM Bielefeld participated to raise awareness about Cystic Fibrosis (CF) and gene therapy. They engaged children through interactive experiments, such as creating lung models and simulating mucus to help them understand the challenges faced by CF patients. Adults were informed about their gene therapy project and had meaningful discussions about the implications of CF treatment. Collaborating with other institutions like the life science student initiative btS, the team expanded their outreach. Despite changeable weather, the event was a success in educating the public and improving science communication.</p>],
quote:"Public health insurance operates under an economic efficiency principle, meaning the most cost-effective treatments are preferred. But if gene therapies become the only treatment option for certain conditions, they will likely have to be included in the coverage, which could be a challenge for the system.",
aimofcontact:"The main objective of the contact was to learn from the discussion on issues related to Cystic Fibrosis (CF), gene therapy, health insurance processes and regulatory pathways. In particular, we wanted to understand the real-world challenges and technical aspects of gene editing, especially prime editing, as well as the complexities of approval and reimbursement of gene therapies for CF patients.",
insights:"The regulatory approval process, particularly by the European Medicines Agency (EMA) for advanced medical devices, has highlighted the bureaucratic hurdles that gene therapies must overcome. We learned that such therapies for Cystic Fibrosis have to navigate complex European and German regulatory systems. The discussion on the AMNOG process was crucial. We learnt that the additional benefit of a therapy is assessed for reimbursement by the statutory health insurance funds. We implemented this insight in our project by considering the long-term regulatory and economic effects as important milestones for therapy development. We also gained insight into how public and private health insurers may differ in their reimbursement of such therapies. Public insurers have stricter guidelines, while private insurers can be more flexible, but both require strict justification, especially for rare diseases such as Cystic Fibrosis. Information on newborn screening and genetic counselling covered by public health insurance was crucial to understanding how preventive measures for CF are managed. This underlines the importance of early intervention and diagnosis in our project. Atypical forms of CF, where health insurance companies do not cover treatment due to non-standardised test results, were identified as a key problem. This helped us to recognise the need for more adaptable insurance policies and clearer pathways for the treatment of atypical cases in our project plans. The debate about whether healthcare systems can afford the high costs of gene therapies highlighted an important issue in the current medical landscape. We have incorporated this insight into our project by discussing possible cost-effective alternatives and the need for thorough cost-benefit analysis in the development of treatments.",
implementation:[<p>After the interview, we further tailored our project to focus on a simple delivery method to reduce the therapeutic effort. To gain an overview of the regulatory requirements and to better deliver the project, one of our team members attended a <HPLinktoOtherHPTabtab="gxpcourse"text="GxP course"/> to ensure we met all the necessary standards. To deepen our knowledge of entrepreneurship, we conducted further interviews with start-ups and <OurLinktabId="Further Engagement3H"path="\human-practices"text="industrial companies"/>, which gave us important insights into practical implementation. These steps ensure that our project is not only based on scientific research, but also takes into account the practical, regulatory and social aspects that are crucial to bringing new CF therapies to the market. We are currently developing strategies to successfully implement our ideas and the project in the future.</p>],
implementation:[<p>After the interview, we further tailored our project to focus on a simple delivery method to reduce the therapeutic effort. To gain an overview of the regulatory requirements and to better deliver the project, one of our team members attended a <HPLinktoOtherHPTabtab="gxpcourse"text="GxP course"/> to ensure we met all the necessary standards. To deepen our knowledge of entrepreneurship, we conducted further interviews with start-ups and <OurLinktabId="Further Engagement3H"path="human-practices"text="industrial companies"/>, which gave us important insights into practical implementation. These steps ensure that our project is not only based on scientific research, but also takes into account the practical, regulatory and social aspects that are crucial to bringing new CF therapies to the market. We are currently developing strategies to successfully implement our ideas and the project in the future.</p>],
interview:<>
<QaBoxq="To start with this interview. Do you have any questions about this project?"
a="Are you writing a paper on this, or are you conducting actual laboratory research? Or is it primarily literature review? How does your work look?"/>
